Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
About
About
EQOH
Careers
HCP Jobs
Contact Us
EMJ Gold
search
Subscribe
FREE
Subscribe to EMJ GOLD
Subscribe to EMJ
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
About
About
EQOH
Careers
HCP Jobs
Contact Us
EMJ Gold
Subscribe
FREE
Subscribe to EMJ GOLD
Subscribe to EMJ
Nephrology
Filter
Journals
About
Congress reviews
Abstracts
Articles
Podcasts
Videos & Webinars
News
Infographics
Submit A Paper
Chronic Active Antibody-Mediated Rejection in Renal Transplant Recipients
2
Mins
April 2024
In 2022, over 92,000 kidney transplants were performed globally.1 With advancements in transplant science, 1-year graft survival rates…
Read more
8
Mins
2nd September 2022
Update on New Antigens in the Pathogenesis of Membranous Nephropathy
Previously, membranous nephropathies were divided into primary and secondary categories when the exact mechanism or pathogenetic factor were unknown. Approximately 70% accounted for primary membranous nephropathies. The remaining 30% were called secondary because they developed due to well-known diseases such as autoimmune diseases, tumours, infections, or drug assumptions.
12
Mins
30th June 2022
The Dual Role of Endothelin-1 and Angiotensin II in Disease Progression of Focal Segmental Glomerulosclerosis and IgA Nephropathy
This article details the diagnosis and treatment of IgA nephropathy and focal segmental glomerulosclerosis, as discussed in a symposium delivered as part of the European Renal Association (ERA) 59th Congress in Paris, 19th−22nd May 2022.
11
Mins
30th June 2022
Medium Cut-off Delivering Expanded Haemodialysis Therapy: Improving Clinical and Economic Outcomes in the Real World
In this symposium, the pathological background of the association between the uremic milieu and inflammation and pathways for poor outcomes in patients on haemodialysis (HD)
4
Mins
30th June 2022
Interview: John Sperati
Talking to John Sperati, Director of Nephrology Fellowship Training Program and Associate Professor of Medicine at Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
4
Mins
30th June 2022
The Ground Is Full of Pitfalls: Association of Chronic Kidney Disease, Conflict Zones, and the Quality of Healthcare in Africa
Public health in sub-Saharan African countries is experiencing a double burden of diseases. Unfortunately, the health systems in sub-Saharan Africa are vulnerable, under-resourced, and unable to address these public health issues.
6
Mins
30th June 2022
Interview: Vivek Bhalla
The primary reason is that it’s the most impactful disease that affects nephrology. When I was in training, there was only one medicine…
5
Mins
30th June 2022
Focal Segmental Glomerulosclerosis: Histopathology Discussion
In focal segmental glomerulosclerosis (FSGS), some (not all) glomeruli are affected with sclerosis (focal), and each diseased glomerulus…
6
Mins
30th June 2022
Editor’s Pick: The Renal Effects of SGLT2 Inhibitors
Sodium–glucose co-transporters (SGLT) play an important role in glucose transport across epithelial cells. SGLT1….
Loading posts...
« Previous
1
2
3
4
5
6
…
18
Next »